Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study.

Carcinoid syndrome Gender Gender medicine Neuroendocrine neoplasm Neuroendocrine tumors Prognosis Sex

Journal

Journal of endocrinological investigation

ISSN: 1720-8386

Titre abrégé: J Endocrinol Invest

Pays: Italy

ID NLM: 7806594

Informations de publication

Date de publication:
14 Oct 2023

Historique:

received: 14 07 2023

accepted: 25 09 2023

medline: 15 10 2023

pubmed: 15 10 2023

entrez: 14 10 2023

Statut: aheadofprint

Résumé

The incidence of neuroendocrine neoplasm (NEN) and related carcinoid syndrome (CaS) has increased markedly in recent decades, and women appear to be more at risk than men. As per other tumors, gender may be relevant in influencing the clinical and prognostic characteristics of NEN-associated CS. However, specific data on carcinoid syndrome (CaS) are still lacking. To evaluate gender differences in clinical presentation and outcome of CaS. Retrospective analysis of 144 CaS patients from 20 Italian high-volume centers was conducted. Clinical presentation, tumor characteristics, therapies, and outcomes (progression-free survival, PFS, overall survival, OS) were correlated to gender. Ninety (62.5%) CaS patients were male. There was no gender difference in the site of primary tumor, tumor grade and clinical stage, as well as in treatments. Men were more frequently smokers (37.2%) and alcohol drinkers (17.8%) than women (9.5%, p = 0.002, and 3.7%, p = 0.004, respectively). Concerning clinical presentation, women showed higher median number of symptoms (p = 0.0007), more frequent abdominal pain, tachycardia, and psychiatric disorders than men (53.3% vs 70.4%, p = 0.044; 6.7% vs 31.5%, p = 0.001; 50.9% vs. 26.7%, p = 0.003, respectively). Lymph node metastases at diagnosis were more frequent in men than in women (80% vs 64.8%; p = 0.04), but no differences in terms of PFS (p = 0.51) and OS (p = 0.64) were found between gender. In this Italian cohort, CaS was slightly more frequent in males than females. Gender-related differences emerged in the clinical presentation of CaS, as well as gender-specific risk factors for CaS development. A gender-driven clinical management of these patients should be advisable.

Sections du résumé

BACKGROUND BACKGROUND

PURPOSE OBJECTIVE

To evaluate gender differences in clinical presentation and outcome of CaS.

METHODS METHODS

Retrospective analysis of 144 CaS patients from 20 Italian high-volume centers was conducted. Clinical presentation, tumor characteristics, therapies, and outcomes (progression-free survival, PFS, overall survival, OS) were correlated to gender.

RESULTS RESULTS

Ninety (62.5%) CaS patients were male. There was no gender difference in the site of primary tumor, tumor grade and clinical stage, as well as in treatments. Men were more frequently smokers (37.2%) and alcohol drinkers (17.8%) than women (9.5%, p = 0.002, and 3.7%, p = 0.004, respectively). Concerning clinical presentation, women showed higher median number of symptoms (p = 0.0007), more frequent abdominal pain, tachycardia, and psychiatric disorders than men (53.3% vs 70.4%, p = 0.044; 6.7% vs 31.5%, p = 0.001; 50.9% vs. 26.7%, p = 0.003, respectively). Lymph node metastases at diagnosis were more frequent in men than in women (80% vs 64.8%; p = 0.04), but no differences in terms of PFS (p = 0.51) and OS (p = 0.64) were found between gender.

CONCLUSIONS CONCLUSIONS

In this Italian cohort, CaS was slightly more frequent in males than females. Gender-related differences emerged in the clinical presentation of CaS, as well as gender-specific risk factors for CaS development. A gender-driven clinical management of these patients should be advisable.

Identifiants

DOI: 10.1007/s40618-023-02213-1 PMID: 37837555

pubmed: 37837555

doi: 10.1007/s40618-023-02213-1

pii: 10.1007/s40618-023-02213-1

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Baggio G, Corsini A, Floreani A, Giannini S, Zagonel V (2013) Gender medicine: a task for the third millennium. Clin Chem Lab Med 51(4):713–727. https://doi.org/10.1515/cclm-2012-0849

doi: 10.1515/cclm-2012-0849 pubmed: 23515103

Muscogiuri G et al (2020) Pancreatic Neuroendocrine Neoplasms: does sex matter? Trends Endocrinol Metab 31(9):631–641. https://doi.org/10.1016/j.tem.2020.02.010

doi: 10.1016/j.tem.2020.02.010 pubmed: 32223919

Muscogiuri G et al (2020) Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine 69(2):441–450. https://doi.org/10.1007/s12020-020-02331-3

doi: 10.1007/s12020-020-02331-3 pubmed: 32468269

Mogl MT et al (2020) Influence of gender on therapy and outcome of neuroendocrine tumors of gastroenteropancreatic origin: a single-center analysis. Visc Med 36(1):20–27. https://doi.org/10.1159/000505500

doi: 10.1159/000505500 pubmed: 32110653 pmcid: 7036565

Halperin DM et al (2017) Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 18(4):525–534. https://doi.org/10.1016/S1470-2045(17)30110-9

doi: 10.1016/S1470-2045(17)30110-9 pubmed: 28238592 pmcid: 6066284

Kimbrough CW et al (2019) Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery 165(3):657–663. https://doi.org/10.1016/j.surg.2018.09.008

doi: 10.1016/j.surg.2018.09.008 pubmed: 30377003

Pandit S, Annamaraju P, Bhusal K (2023) Carcinoid Syndrome

Fanciulli G et al (2020) Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications. Rev Endocr Metab Disord 21(4):599–612. https://doi.org/10.1007/s11154-020-09547-8

doi: 10.1007/s11154-020-09547-8 pubmed: 32152781

Fröjd C, Larsson G, Lampic C, von Essen L (2007) Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual Life Outcomes 5:18. https://doi.org/10.1186/1477-7525-5-18

doi: 10.1186/1477-7525-5-18 pubmed: 17428340 pmcid: 1852299

Ruggeri RM et al (2022) Sex differences in carcinoid syndrome: a gap to be closed. Rev Endocr Metab Disord 23(3):659–669. https://doi.org/10.1007/s11154-022-09719-8

doi: 10.1007/s11154-022-09719-8 pubmed: 35292889

Cai B, Broder MS, Chang E, Yan T, Metz DC (2017) Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. World J Gastroenterol 23(40):7283–7291. https://doi.org/10.3748/wjg.v23.i40.7283

doi: 10.3748/wjg.v23.i40.7283 pubmed: 29142475 pmcid: 5677203

Fu M et al (2022) Gender differences in pancreatic neuroendocrine neoplasms: a retrospective study based on the population of Hubei Province, China. Front Endocrinol 13:885895. https://doi.org/10.3389/fendo.2022.885895

doi: 10.3389/fendo.2022.885895

“NHIS - Special Topics from the National Health Interview Survey.” https://www.cdc.gov/nchs/nhis/special_topics.htm (accessed Apr. 05, 2023)

Rindi G et al (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33(1):115–154. https://doi.org/10.1007/s12022-022-09708-2

doi: 10.1007/s12022-022-09708-2 pubmed: 35294740

Amin MB et al. (2017) American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. Accessed: Apr. 05, 2023. [Online]. Available: https://link.springer.com/book/9783319406176

Man D, Wu J, Shen Z, Zhu X (2018) Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res 10:5629–5638. https://doi.org/10.2147/CMAR.S174907

doi: 10.2147/CMAR.S174907 pubmed: 30519109 pmcid: 6239108

Abdel-Rahman O, Fazio N (2021) Sex-based differences in prognosis of patients with gastroenteropancreatic-neuroendocrine neoplasms: a population-based study. Pancreas 50(5):727–731. https://doi.org/10.1097/MPA.0000000000001821

doi: 10.1097/MPA.0000000000001821 pubmed: 34016894

Genus TSE et al (2019) Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015. Br J Cancer 121(11):966–972. https://doi.org/10.1038/s41416-019-0606-3

doi: 10.1038/s41416-019-0606-3 pubmed: 31649320 pmcid: 6889414

Wyld D, Wan MH, Moore J, Dunn N, Youl P (2019) Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia. Cancer Epidemiol 63:101598. https://doi.org/10.1016/j.canep.2019.101598

doi: 10.1016/j.canep.2019.101598 pubmed: 31539715

White BE et al (2022) Incidence and survival of neuroendocrine neoplasia in England 1995–2018: A retrospective, population-based study. Lancet Region Health Europe 23:100510. https://doi.org/10.1016/j.lanepe.2022.100510

doi: 10.1016/j.lanepe.2022.100510

White BE et al (2023) Sex differences in survival from neuroendocrine neoplasia in England 2012–2018: a retrospective, population-bases study. Cancers (Basel). https://doi.org/10.3390/cancers15061863

doi: 10.3390/cancers15061863 pubmed: 37509399

Estrella JS et al (2014) Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas 43(7):996–1002. https://doi.org/10.1097/MPA.0000000000000203

doi: 10.1097/MPA.0000000000000203 pubmed: 25058880 pmcid: 4628823

Blažević A et al (2018) Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocr Relat Cancer 25(3):245–254. https://doi.org/10.1530/ERC-17-0282

doi: 10.1530/ERC-17-0282 pubmed: 29255095

Blažević A et al (2021) Evolution of the mesenteric mass in small intestinal neuroendocrine tumours. Cancers (Basel). https://doi.org/10.3390/cancers13030443

doi: 10.3390/cancers13030443 pubmed: 33503893

Blažević A et al (2022) Sexual dimorphism in small-intestinal neuroendocrine tumors: lower prevalence of mesenteric disease in premenopausal women. J Clin Endocrinol Metab 107(5):e1969–e1975. https://doi.org/10.1210/clinem/dgac001

doi: 10.1210/clinem/dgac001 pubmed: 34999838 pmcid: 9016466

Arnason T, Sapp HL, Barnes PJ, Drewniak M, Abdolell M, Rayson D (2011) Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors. Neuroendocrinology 93(4):249–258. https://doi.org/10.1159/000326820

doi: 10.1159/000326820 pubmed: 21487213

Estrella JS et al (2014) Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med 138(8):1027–1036. https://doi.org/10.5858/arpa.2013-0195-OA

doi: 10.5858/arpa.2013-0195-OA pubmed: 25076292

Barros M et al (2019) HORMONET: Study of tamoxifen in well differentiated neuroendocrine tumours and hormone receptor positive expression. Ann Oncol 30:v573. https://doi.org/10.1093/annonc/mdz256.024

doi: 10.1093/annonc/mdz256.024

Mauvais-Jarvis F et al (2020) Sex and gender: modifiers of health, disease, and medicine. Lancet 396(10250):565–582. https://doi.org/10.1016/S0140-6736(20)31561-0

doi: 10.1016/S0140-6736(20)31561-0 pubmed: 32828189 pmcid: 7440877

Clocchiatti A, Cora E, Zhang Y, Dotto GP (2016) Sexual dimorphism in cancer. Nat Rev Cancer 16(5):330–339. https://doi.org/10.1038/nrc.2016.30

doi: 10.1038/nrc.2016.30 pubmed: 27079803

Wagner AD et al (2019) Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol 30(12):1914–1924. https://doi.org/10.1093/annonc/mdz414

doi: 10.1093/annonc/mdz414 pubmed: 31613312

De León-Nava MA et al (2009) Immune sexual dimorphism: effect of gonadal steroids on the expression of cytokines, sex steroid receptors, and lymphocyte proliferation. J Steroid Biochem Mol Biol 113(1–2):57–64. https://doi.org/10.1016/j.jsbmb.2008.11.003

doi: 10.1016/j.jsbmb.2008.11.003 pubmed: 19073259

Hemminki K, Li X (2001) Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 92(8):2204–2210. https://doi.org/10.1002/1097-0142(20011015)92:8%3c2204::aid-cncr1564%3e3.0.co;2-r

doi: 10.1002/1097-0142(20011015)92:8<2204::aid-cncr1564>3.0.co;2-r pubmed: 11596039

Nicholas DR (2000) Men, masculinity, and cancer: risk-factor behaviors, early detection, and psychosocial adaptation. J Am Coll Health 49(1):27–33. https://doi.org/10.1080/07448480009596279

doi: 10.1080/07448480009596279 pubmed: 10967881

Barrea L et al (2021) Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors. Front Endocrinol (Lausanne) 12:649496. https://doi.org/10.3389/fendo.2021.649496

doi: 10.3389/fendo.2021.649496 pubmed: 33815296

Barrea L et al (2018) Impact of nutritional status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) aggressiveness. Nutrients. https://doi.org/10.3390/nu10121854

doi: 10.3390/nu10121854 pubmed: 30597889 pmcid: 6356593

Vigneri R, Goldfine ID, Frittitta L (2016) Insulin, insulin receptors, and cancer. J Endocrinol Invest 39(12):1365–1376. https://doi.org/10.1007/s40618-016-0508-7

doi: 10.1007/s40618-016-0508-7 pubmed: 27368923

Gallo M et al (2018) Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any? Cancer Treat Rev 67:1–9. https://doi.org/10.1016/j.ctrv.2018.04.013

doi: 10.1016/j.ctrv.2018.04.013 pubmed: 29746922

Herrera-Martínez AD et al (2019) Type 2 diabetes in neuroendocrine tumors: are biguanides and statins part of the solution? J Clin Endocrinol Metab 104(1):57–73. https://doi.org/10.1210/jc.2018-01455

doi: 10.1210/jc.2018-01455 pubmed: 30265346

Gallo M et al (2019) The management of neuroendocrine tumours: a nutritional viewpoint. Crit Rev Food Sci Nutr 59(7):1046–1057. https://doi.org/10.1080/10408398.2017.1390729

doi: 10.1080/10408398.2017.1390729 pubmed: 29020456

Feola T et al (2022) Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J Endocrinol Invest 45(4):849–857. https://doi.org/10.1007/s40618-021-01715-0

doi: 10.1007/s40618-021-01715-0 pubmed: 35040099

Jann H et al (2023) Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe. J Cancer Res Clin Oncol. https://doi.org/10.1007/s00432-023-04711-4

doi: 10.1007/s00432-023-04711-4 pubmed: 37318593 pmcid: 10423109

Yao JC et al (2008) One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072. https://doi.org/10.1200/JCO.2007.15.4377

doi: 10.1200/JCO.2007.15.4377 pubmed: 18565894

Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121(4):589–597. https://doi.org/10.1002/cncr.29099

doi: 10.1002/cncr.29099 pubmed: 25312765

Boyar Cetinkaya R, Aagnes B, Myklebust TÅ, Thiis-Evensen E (2018) Survival in neuroendocrine neoplasms; a report from a large Norwegian population-based study. Int J Cancer 142(6):1139–1147. https://doi.org/10.1002/ijc.31137

doi: 10.1002/ijc.31137 pubmed: 29082524

Miao D-L et al (2018) Development and validation of a nomogram for predicting overall survival in pancreatic neuroendocrinetumors. Transl Oncol 11(5):1097–1103. https://doi.org/10.1016/j.tranon.2018.06.012

doi: 10.1016/j.tranon.2018.06.012 pubmed: 30015262 pmcid: 6070700